What is the primary use of cefuroxime axetil?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cefuroxime Axetil Primary Use

Cefuroxime axetil is primarily used as an oral second-generation cephalosporin for treating community-acquired bacterial respiratory tract infections, including acute bacterial sinusitis, pharyngitis/tonsillitis, acute otitis media, and community-acquired pneumonia, as well as skin/soft tissue infections and urinary tract infections. 1

FDA-Approved Indications

According to the FDA drug label, cefuroxime axetil for oral suspension is specifically indicated for pediatric patients (3 months to 12 years) with mild to moderate infections caused by susceptible organisms 1:

  • Pharyngitis/Tonsillitis caused by Streptococcus pyogenes
  • Acute Bacterial Otitis Media caused by S. pneumoniae, H. influenzae (including beta-lactamase-producing strains), M. catarrhalis (including beta-lactamase-producing strains), or S. pyogenes
  • Impetigo caused by S. aureus (including beta-lactamase-producing strains) or S. pyogenes

Primary Clinical Applications Based on Guidelines

Respiratory Tract Infections

Cefuroxime axetil is most commonly prescribed for respiratory tract infections, representing its principal clinical use 2, 3, 4, 5.

For acute bacterial sinusitis, cefuroxime axetil is recommended as first-line therapy alongside amoxicillin-clavulanate and certain third-generation cephalosporins 3. The guidelines specifically note that cefuroxime axetil has "significantly enhanced activity against β-lactamase-producing H. influenzae, M. catarrhalis, and S. aureus" with the advantage of twice-daily administration 2.

For community-acquired pneumonia in adults, cefuroxime axetil serves as part of combination therapy (β-lactam plus macrolide) for outpatients with comorbidities or risk factors for drug-resistant S. pneumoniae 6. The recommended regimen is cefuroxime 500 mg twice daily combined with a macrolide.

Early Lyme Disease

Cefuroxime axetil (500 mg twice daily for 14-21 days) is one of three first-line oral antibiotics for early localized or early disseminated Lyme disease associated with erythema migrans 7. It is equally effective as doxycycline and amoxicillin for this indication.

Acute Otitis Media

In pediatric patients, cefuroxime axetil is recommended for acute otitis media, particularly when β-lactamase-producing organisms are suspected 3, 8. However, the guidelines note that "cefuroxime axetil is unpalatable in suspension," which may limit adherence in young children 2.

Key Microbiological Coverage

Cefuroxime axetil's primary utility stems from its activity against the most common community-acquired respiratory pathogens 4, 9, 10:

  • Streptococcus pneumoniae (including penicillin-susceptible and intermediate strains)
  • Haemophilus influenzae (including β-lactamase producers)
  • Moraxella catarrhalis (including β-lactamase producers)
  • Streptococcus pyogenes
  • Methicillin-sensitive Staphylococcus aureus

Important Clinical Caveats

First-generation cephalosporins like cephalexin have poor coverage for H. influenzae and are inappropriate for respiratory infections 2. Cefuroxime axetil, as a second-generation agent, overcomes this limitation.

The drug should not be used for penicillin-resistant S. pneumoniae with high-level resistance, as one report suggested worse outcomes when cefuroxime was used to treat pneumococcal bacteremia with resistant organisms 6.

Cefuroxime axetil tablets and oral suspension are not bioequivalent and cannot be substituted on a milligram-per-milligram basis 1. The suspension actually achieves higher drug exposure and can cover MICs up to 1.0 mg/L, compared to 0.5 mg/L for the 500 mg tablet 11.

The typical adult dosing is 250-500 mg twice daily, with the specific dose depending on infection severity and site 1, 4, 9. Treatment duration is generally 5-14 days for most respiratory infections, with shorter 5-day courses shown to be as effective as 10-day courses for certain indications 4, 9.

References

Guideline

the diagnosis and management of sinusitis: a practice parameter update.

Journal of Allergy and Clinical Immunology, 2005

Guideline

antimicrobial treatment guidelines for acute bacterial rhinosinusitis.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2004

Research

Cefuroxime axetil.

International journal of antimicrobial agents, 1994

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.